| I-30 Joachim Grevel Exposure-response analysis for efficacy and safety of sorafenib in patients with differentiated thyroid carcinoma (DTC) Wednesday 10:20-11:40 |
| I-30 Joachim Grevel Exposure-response analysis for efficacy and safety of sorafenib in patients with differentiated thyroid carcinoma (DTC) Wednesday 10:20-11:40 |